vitals-149/89; cobblestoning posterior pharynx; sensation of throat closing; nausea; pruritis; allergic reaction; tired; flushing; itchy throat/ scratchy throat; erythema/ Localized Erythema; burning pain at site; confusion; trouble swallowing; Blurry vision; Ringing ears; Headache; arm soreness; injection site noted improved with very pale pink discoloration noted to site; This is a spontaneous report from a contactable consumer or other non hcp. This is a report received from for self via FDA (VAERS Number: 903469). A 46-years-old female patient received bnt162b2 (BNT162B2), dose 1 intramuscular, administered in Arm Right on 17Dec2020 17:30 (Batch/Lot Number: EK5730 exp date :Mar2021) as DOSE 1, SINGLE for covid-19 immunisation. Medical history included rubber sensitivity from an unknown date and unknown if ongoing Allergies to medications, food, or other products: Latex , food allergy from an unknown date and unknown if ongoing Allergies to medications, food, or other products: Pine nuts , hypothyroidism from an unknown date and unknown if ongoing , osteoarthritis from an unknown date and unknown if ongoing , anaphylactic reaction from an unknown date and unknown if ongoing Allergies to medications, food, or other products: Latex-Anaphylaxis , dermatitis contact from an unknown date and unknown if ongoing Allergies to medications, food, or other products: Tape. Concomitant medication(s) included sambucus nigra fruit (ELDERBERRY [SAMBUCUS NIGRA FRUIT]) taken for an unspecified indication, start and stop date were not reported; butalbital, caffeine, paracetamol (FIORICET) taken for an unspecified indication, start and stop date were not reported; levothyroxine (LEVOTHYROXINE) taken for an unspecified indication, start and stop date were not reported; meloxicam (MELOXICAM) taken for an unspecified indication, start and stop date were not reported; ascorbic acid, bioflavonoids nos (VITAMIN C [ASCORBIC ACID;BIOFLAVONOIDS NOS]) taken for an unspecified indication, start and stop date were not reported. The patient was allergic to Levothyroxine, fioricet, Vitamin C. The patient previously took codeine, hydrocodone and experienced drug hypersensitivity, hydrocodone and experienced anaphylactic reaction, influenza vaccine and experienced erythema. After receiving the first dose of bnt162b2, the patient experienced flushing on 17Dec2020 19:58, burning pain at site on 17Dec2020 17:40, itchy throat/ scratchy throat on 17Dec2020 17:58, confusion on 17Dec2020, trouble swallowing on 17Dec2020, erythema on 17Dec2020 17:58, blurry vision on 17Dec2020, ringing ears on 17Dec2020, headache on 17Dec2020, arm soreness on 17Dec2020, injection site noted improved with very pale pink discoloration noted to site on 17Dec2020, tired on 18Dec2020, vitals-149/89. On an unspecified date, the patient's spo2 was 98%. The patient had cobblestoning posterior pharynx, sensation of throat closing, nausea, pruritis, allergic reaction. The patient had an emergency room and physician office visit for the events. Therapeutic measures were taken as a result of flushing, burning pain at site, itchy throat, confusion, trouble swallowing, erythema, blurry vision, ringing ears, headache was ice pack, Benadryl 50mg po via oral route of administration and Solumedrol 125mg IM X1 via intramuscular route of administration. The patient was treated with Epi 0.3 mg 1M, Sodium Chloride 0.9 %, Diphenhydramine 25mg IVP, Ondansetron 4mg IVP, cetirizine 10 mg PO, Famotidine 20 mg PO. The outcome of the events flushing, burning pain at site, itchy throat/ scratchy throat, confusion, trouble swallowing, erythema/ Localized Erythema, Blurry vision, Ringing ears, Headache was reported as recovered on 22Dec2020. The outcome of the events arm soreness was reported as recovered on an unspecified date. The outcome of the events tired was reported as recovering at the time of report. The outcome of the events Vaccination site discolouration, Blood pressure increased, Cobble stone pharynx, Throat constriction, nausea, pruritis, allergic reaction was reported as unknown.  Follow-up (08Mar2021): New information received from a contactable consumer included correct lot number, event and treatment details.  Follow-up attempts are completed. No further information is expected.